Considering the Future of Pediatric Multiple Sclerosis Trials After the CONNECT Open-Label Randomized Trial

Omar Abdel-Mannan^{1

2}, Olga Ciccarelli^{1

3}, Yael Hacohen^{1

2}

Affiliations

¹ Queen Square MS Centre, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, United Kingdom.
² Department of Neurology, Great Ormond Street Hospital for Children, London, United Kingdom.
³ NIHR University College London Hospitals Biomedical Research Centre, London, United Kingdom.

Free article

Comment

Omar Abdel-Mannan et al. JAMA Netw Open. 2022.

Free article

. 2022 Sep 1;5(9):e2230451.

doi: 10.1001/jamanetworkopen.2022.30451.

Omar Abdel-Mannan^{1

2}, Olga Ciccarelli^{1

3}, Yael Hacohen^{1

2}

¹ Queen Square MS Centre, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, United Kingdom.
² Department of Neurology, Great Ormond Street Hospital for Children, London, United Kingdom.
³ NIHR University College London Hospitals Biomedical Research Centre, London, United Kingdom.

No abstract available

Comment on

Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial.
Vermersch P, Scaramozza M, Levin S, Alroughani R, Deiva K, Pozzilli C, Lyons J, Mokliatchouk O, Pultz J, N'Dure F, Liu S, Badwan R, Branco F, Hood-Humphrey V, Franchimont N, Hanna J, Maghzi AH. Vermersch P, et al. JAMA Netw Open. 2022 Sep 1;5(9):e2230439. doi: 10.1001/jamanetworkopen.2022.30439. JAMA Netw Open. 2022. PMID: 36169959 Free PMC article. Clinical Trial.